Weaver C. Barksdale & Associates’s Elevance Health ELV Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.6M	Buy	5,469 +336	+7%	+$110K	1.53%	42
2025 Q4	$1.8M	Buy	5,133 +757	+17%	+$256K	1.89%	21
2025 Q3	$1.41M	Sell	4,376 -278	-6%	-$86.5K	1.36%	43
2025 Q2	$1.81M	Sell	4,654 -39	-0.8%	-$15.7K	1.73%	30
2025 Q1	$2.04M	Sell	4,693 -110	-2%	-$44.2K	1.96%	16
2024 Q4	$1.77M	Buy	+4,803	New	+$2.01M	1.7%	28

Other funds holding ELV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Weaver C. Barksdale & Associates's ELV Position: Q1 2026 in Review

Weaver C. Barksdale & Associates increased its Elevance Health (ELV) stake by 6.5% in Q1 2026, buying an estimated $110K and bringing the position to 5,469 shares worth $1.6M. The position accounts for 1.53% of the portfolio, ranked #42.

Weaver C. Barksdale & Associates first reported a position in ELV in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.04M in Q1 2025. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

Weaver C. Barksdale & Associates held 5,469 shares of Elevance Health worth $1.6M as of Q1 2026.
Weaver C. Barksdale & Associates bought 336 Elevance Health shares in Q1 2026, an estimated $110K.
Elevance Health made up 1.53% of Weaver C. Barksdale & Associates's portfolio in Q1 2026, its #42 holding.
Weaver C. Barksdale & Associates first reported a position in Elevance Health in Q4 2024 and has held it in 6 quarters since.
Weaver C. Barksdale & Associates's Elevance Health position peaked at $2.04M in Q1 2025.
1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on Weaver C. Barksdale & Associates's 13F filing for Q1 2026, filed 14 May 2026.